Literature DB >> 11533162

Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus.

D Durantel1, N Branza-Nichita, S Carrouée-Durantel, T D Butters, R A Dwek, N Zitzmann.   

Abstract

The glucose-derived iminosugar derivatives N-butyl- and N-nonyl-deoxynojirimycin (DNJ) have an antiviral effect against a broad spectrum of viruses including Bovine viral diarrhea virus (BVDV). For BVDV, this effect has been attributed to the reduction of viral secretion due to an impairment of viral morphogenesis caused by the ability of DNJ-based iminosugar derivatives to inhibit ER alpha-glucosidases (N. Zitzmann, A. S. Mehta, S. Carrouée, T. D. Butters, F. M. Platt, J. McCauley, B. S. Blumberg, R. A. Dwek, and T. M. Block, Proc. Natl. Acad. Sci. USA 96:11878-11882, 1999). Here we present the antiviral features of newly designed DNJ derivatives and report for the first time the antiviral activity of long-alkyl-chain derivatives of deoxygalactonojirimycin (DGJ), a class of iminosugars derived from galactose which does not inhibit endoplasmic reticulum (ER) alpha-glucosidases. We demonstrate the lack of correlation between the ability of long-alkyl-chain DNJ derivatives to inhibit ER alpha-glucosidases and their antiviral effect, ruling out ER alpha-glucosidase inhibition as the sole mechanism responsible. Using short- and long-alkyl-chain DNJ and DGJ derivatives, we investigated the mechanisms of action of these drugs. First, we excluded their potential action at the level of the replication, protein synthesis, and protein processing. Second, we demonstrated that DNJ derivatives cause both a reduction in viral secretion and a reduction in the infectivity of newly released viral particles. Long-alkyl-chain DGJ derivatives exert their antiviral effect solely via the production of viral particles with reduced infectivity. We demonstrate that long-alkyl-chain DNJ and DGJ derivatives induce an increase in the quantity of E2-E2 dimers accumulated within the ER. The subsequent enrichment of these homodimers in secreted virus particles correlates with their reduced infectivity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11533162      PMCID: PMC114467          DOI: 10.1128/JVI.75.19.8987-8998.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum.

Authors:  M P Courageot; M P Frenkiel; C D Dos Santos; V Deubel; P Desprès
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disorders.

Authors:  T D Butters; R A Dwek; F M Platt
Journal:  Chem Rev       Date:  2000-12-13       Impact factor: 60.622

3.  Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction.

Authors:  T Horikoshi; K D Danenberg; T H Stadlbauer; M Volkenandt; L C Shea; K Aigner; B Gustavsson; L Leichman; R Frösing; M Ray
Journal:  Cancer Res       Date:  1992-01-01       Impact factor: 12.701

4.  Variation in the intracellular polypeptide profiles from different isolates of bovine virus diarrhoea virus.

Authors:  D H Pocock; C J Howard; M C Clarke; J Brownlie
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

5.  Antiviral effect of N-butyldeoxynojirimycin against bovine viral diarrhea virus correlates with misfolding of E2 envelope proteins and impairment of their association into E1-E2 heterodimers.

Authors:  N Branza-Nichita; D Durantel; S Carrouée-Durantel; R A Dwek; N Zitzmann
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

6.  Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents.

Authors:  N Zitzmann; A S Mehta; S Carrouée; T D Butters; F M Platt; J McCauley; B S Blumberg; R A Dwek; T M Block
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

7.  Aminosugar derivatives as potential anti-human immunodeficiency virus agents.

Authors:  A Karpas; G W Fleet; R A Dwek; S Petursson; S K Namgoong; N G Ramsden; G S Jacob; T W Rademacher
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

8.  The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding.

Authors:  P B Fischer; M Collin; G B Karlsson; W James; T D Butters; S J Davis; S Gordon; R A Dwek; F M Platt
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

9.  Inhibition of HIV replication by amino-sugar derivatives.

Authors:  G W Fleet; A Karpas; R A Dwek; L E Fellows; A S Tyms; S Petursson; S K Namgoong; N G Ramsden; P W Smith; J C Son
Journal:  FEBS Lett       Date:  1988-09-12       Impact factor: 4.124

10.  Folding of VSV G protein: sequential interaction with BiP and calnexin.

Authors:  C Hammond; A Helenius
Journal:  Science       Date:  1994-10-21       Impact factor: 47.728

View more
  36 in total

Review 1.  The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?

Authors:  Martin McLaughlin; Koen Vandenbroeck
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

2.  Antiviral effects of an iminosugar derivative on flavivirus infections.

Authors:  Shu-Fen Wu; Chyan-Jang Lee; Ching-Len Liao; Raymond A Dwek; Nicole Zitzmann; Yi-Ling Lin
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  Synthetic N-alkylated iminosugars as new potential immunosuppressive agents.

Authors:  Guan-Nan Wang; Yulan Xiong; Jia Ye; Li-He Zhang; Xin-Shan Ye
Journal:  ACS Med Chem Lett       Date:  2011-07-05       Impact factor: 4.345

4.  Acid-resistant bovine pestivirus requires activation for pH-triggered fusion during entry.

Authors:  Thomas Krey; Heinz-Jürgen Thiel; Till Rümenapf
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Structure-activity relationship of a new class of anti-hepatitis B virus agents.

Authors:  Anand Mehta; Bertha Conyers; D L J Tyrrell; Kathie-Anne Walters; Graham A Tipples; Raymond A Dwek; Timothy M Block
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

6.  Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.

Authors:  Wenquan Yu; Tina Gill; Lijuan Wang; Yanming Du; Hong Ye; Xiaowang Qu; Ju-Tao Guo; Andrea Cuconati; Kang Zhao; Timothy M Block; Xiaodong Xu; Jinhong Chang
Journal:  J Med Chem       Date:  2012-06-29       Impact factor: 7.446

7.  Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses.

Authors:  Jinhong Chang; Lijuan Wang; Dongling Ma; Xiaowang Qu; Haitao Guo; Xiaodong Xu; Peter M Mason; Nigel Bourne; Robert Moriarty; Baohua Gu; Ju-Tao Guo; Timothy M Block
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

8.  Membrane disruption and cytotoxicity of hydrophobic N-alkylated imino sugars is independent of the inhibition of protein and lipid glycosylation.

Authors:  Howard R Mellor; Frances M Platt; Raymond A Dwek; Terry D Butters
Journal:  Biochem J       Date:  2003-09-01       Impact factor: 3.857

Review 9.  Differential sensitivity of mouse strains to an N-alkylated imino sugar: glycosphingolipid metabolism and acrosome formation.

Authors:  Aarnoud C van der Spoel; Richard Mott; Frances M Platt
Journal:  Pharmacogenomics       Date:  2008-06       Impact factor: 2.533

10.  Cellular effects of deoxynojirimycin analogues: inhibition of N-linked oligosaccharide processing and generation of free glucosylated oligosaccharides.

Authors:  Howard R Mellor; David C A Neville; David J Harvey; Frances M Platt; Raymond A Dwek; Terry D Butters
Journal:  Biochem J       Date:  2004-08-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.